Advertisement

Response to van Riel et al

Published:November 16, 2022DOI:https://doi.org/10.1016/j.gim.2022.10.008
      Long before the availability of genomic sequencing technologies, initial descriptions of Mendelian disorders relied on clinical observation of individual patients and families. Medical dysmorphology and detailed pedigrees provided evidence for inheritance patterns while occasionally allowing a glimpse of variable expressivity and the milder end of the phenotypic spectrum for some disorders. Most well-established genetic syndromes were first discovered clinically in patients with classic manifestations and later matched to pathogenic variants in previously unknown genes. Separately, more genotyping and genomic sequencing of large cohorts have revealed associations between pathogenic variants and more common disorders, such as the dozens of pathogenic copy number variants that broadly correlate with an array of medical and neurodevelopmental diagnoses.
      • Martin C.L.
      • Wain K.E.
      • Oetjens M.T.
      • et al.
      Identification of neuropsychiatric copy number variants in a health care system population.
      For both categories—well known, clinically defined Mendelian syndromes and newer, poorly phenotyped pathogenic variants identified via clinical cohorts—important questions remain about population prevalence, clinical penetrance, phenotypic spectrum, and disease risk. The recent availability of large-scale data sets from multiple biobanks, including Geisinger’s MyCode, the UK Biobank, and other genome-first population-based initiatives, has begun to reveal surprising differences from historically estimated disease prevalence and penetrance outside of medically ascertained patients and families.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      ACMG Member Login

      Are you an ACMG Member? Sign in for online access.

      Subscribe:

      Subscribe to Genetics in Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Martin C.L.
        • Wain K.E.
        • Oetjens M.T.
        • et al.
        Identification of neuropsychiatric copy number variants in a health care system population.
        JAMA Psychiatry. 2020; 77 (Published correction appears in JAMA Psychiatry. 2020;77(12):1310. https://doi.org/10.1001/jamapsychiatry.2020.2159): 1276-1285
        • Savatt J.M.
        • Shimelis H.
        • Moreno-De-Luca A.
        • et al.
        Frequency of truncating FLCN variants and Birt-Hogg-Dubé-associated phenotypes in a health care system population.
        Genet Med. 2022; 24: 1857-1866https://doi.org/10.1016/j.gim.2022.05.006
        • Schmidt L.S.
        • Linehan W.M.
        FLCN: the causative gene for Birt-Hogg-Dubé syndrome.
        Gene. 2018; 640: 28-42https://doi.org/10.1016/j.gene.2017.09.044
        • Lagerstedt-Robinson K.
        • Baranowska Körberg I.
        • Tsiaprazis S.
        • et al.
        A retrospective two centre study of Birt-Hogg-Dubé syndrome reveals a pathogenic founder mutation in FLCN in the Swedish population.
        PLoS One. 2022; 17e0264056https://doi.org/10.1371/journal.pone.0264056
        • van Riel L.
        • Jansen P.
        • Boerrigter B.G.
        • et al.
        Comment on “Frequency of truncating FLCN variants and Birt-Hogg-Dubé associated phenotypes in a health care system population” by Savatt et al.
        Genet Med. 2022;
        • Kingdom R.
        • Tuke M.
        • Wood A.
        • et al.
        Rare genetic variants in genes and loci linked to dominant monogenic developmental disorders cause milder related phenotypes in the general population.
        Am J Hum Genet. 2022; 109: 1308-1316https://doi.org/10.1016/j.ajhg.2022.05.011
        • Forrest I.S.
        • Chaudhary K.
        • Vy H.M.T.
        • et al.
        Population-based penetrance of deleterious clinical variants.
        JAMA. 2022; 327: 350-359https://doi.org/10.1001/jama.2021.23686
        • Mirshahi U.L.
        • Kim J.
        • Best A.F.
        • et al.
        A genome-first approach to characterize DICER1 pathogenic variant prevalence, penetrance, and phenotype.
        JAMA Netw Open. 2021; 4e210112https://doi.org/10.1001/jamanetworkopen.2021.0112
        • Kingdom R.
        • Wright C.F.
        Incomplete penetrance and variable expressivity: from clinical studies to population cohorts.
        Front Genet. 2022; 13920390https://doi.org/10.3389/fgene.2022.920390
        • Fry A.
        • Littlejohns T.J.
        • Sudlow C.
        • et al.
        Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population.
        Am J Epidemiol. 2017; 186: 1026-1034https://doi.org/10.1093/aje/kwx246

      Linked Article